STX — Shield Therapeutics Share News
0.000.00%
Last trade - 00:00- £72.65m
- £86.55m
- $49.70m
REG - Shield Therapeutics - Unaudited full year trading update
AnnouncementREG - Shield Therapeutics - Anders Lundstrom appointed CEO
AnnouncementREG - AIM - AIM Notice - 30/12/2024
AnnouncementREG - Shield Therapeutics - Result of General Meeting & Total Voting Rights
AnnouncementREG - Shield Therapeutics - Results of RetailBook Offer
AnnouncementREG - Shield Therapeutics - RetailBook Offer
AnnouncementREG - Shield Therapeutics - Subscription by AOP Health to raise US$10 million
AnnouncementREG - Shield Therapeutics - Business Update
AnnouncementREG - Shield Therapeutics - Q3 Trading Update
AnnouncementREG - Shield Therapeutics - Results from Phase 3 paediatric study
AnnouncementREG - Shield Therapeutics - Interim results
AnnouncementREG - Shield Therapeutics - ACCRUFeR® Approved by Health Canada
AnnouncementREG - Shield Therapeutics - Notice of interim results
AnnouncementREG - Shield Therapeutics - Unaudited Q2 2024 Trading Update
AnnouncementREG - Shield Therapeutics - Directorate Change
AnnouncementREG - Shield Therapeutics - $5.7m Milestone Monetization Agreement with AOP
AnnouncementREG - Shield Therapeutics - Results of 2024 Annual General Meeting
AnnouncementREG - Shield Therapeutics - New Drug Application for Accrufer® in South Korea
AnnouncementREG - Shield Therapeutics - Audited results for the year ended 31 Dec 2023
Announcement